SARS-CoV-2 actively sabotages your immune defenses from the moment it enters your cells. Unlike many respiratory viruses that simply outrun the immune response, COVID deploys at least 16 of its 28 known proteins specifically to disarm different branches of your immune system. This disruption can range from a brief delay in your body’s antiviral alarm system to, in severe cases, a cascade of immune dysfunction that persists for months.
How the Virus Disables Your First Line of Defense
Your innate immune system is supposed to respond within hours of detecting a new virus. A key part of that early alarm involves signaling molecules called interferons, which alert neighboring cells to mount an antiviral defense. SARS-CoV-2 is unusually effective at suppressing this system. Multiple viral proteins work together to block interferon production at nearly every step, from initial virus detection inside the cell to the final export of warning signals.
The virus’s M protein destabilizes the molecular complex your cells use to detect viral genetic material. Other proteins block the activation of key signaling molecules that would normally trigger interferon release. One viral protein, ORF6, physically prevents a critical signaling molecule from entering the cell nucleus where it needs to go to switch on antiviral genes. Yet another, NSP1, jams the machinery that exports cellular messages out of the nucleus entirely, effectively silencing the cell’s ability to communicate the threat.
The practical result: people who mount a strong interferon response early tend to clear the virus faster and experience milder symptoms. When that early response is delayed or suppressed, viral levels in the blood climb higher, and the risk of severe disease increases substantially. This is one reason COVID can feel deceptively mild in the first few days before symptoms suddenly worsen.
The Inflammatory Overcorrection
Because the virus delays the early alarm, the immune system often plays catch-up by launching an exaggerated inflammatory response later. When the body finally recognizes the scale of the infection, it can flood the bloodstream with inflammatory signals. In severe cases, this becomes a self-reinforcing loop sometimes called a cytokine storm, where inflammation damages healthy tissue, particularly in the lungs, blood vessels, and organs far from the original site of infection.
This overcorrection explains a pattern seen throughout the pandemic: the most dangerous phase of COVID often isn’t the initial viral infection itself but the body’s own inflammatory response days later. Lung damage, blood clotting problems, and organ failure in hospitalized patients are largely driven by this uncontrolled immune activation rather than the virus directly destroying tissue.
T-Cell Exhaustion and Lymphocyte Loss
COVID also takes a measurable toll on the adaptive immune system, particularly T cells. In severe infections, lymphocyte counts (the white blood cells that include T cells) can drop below 1.5 billion per liter of blood, a threshold that reliably predicts worse outcomes. This drop, called lymphopenia, is one of the most consistent lab findings in serious COVID cases.
Beyond sheer numbers, the T cells that remain can show signs of functional exhaustion. Researchers have found that both CD8+ T cells (which kill infected cells) and CD4+ T cells (which coordinate the broader immune response) display elevated levels of inhibitory markers like PD-1 and TIM-3 during and after infection. These markers essentially act as brakes on T-cell activity. In people with long COVID, increased expression of these exhaustion markers has been documented at 3 and 8 months after infection, though they generally resolve by around 24 months. In severe cases requiring intensive care, T cells also show high levels of activation markers associated with fatal outcomes in other viral infections like H7N9 influenza.
Why Older Adults Are Hit Harder
The age-related pattern of COVID severity ties directly to a gland called the thymus, which produces new T cells. The thymus naturally shrinks with age, a process called involution, and by middle age it produces far fewer fresh T cells than it did in childhood. This means older adults start with a less diverse pool of T cells, making it harder for the immune system to recognize and respond to a novel virus like SARS-CoV-2.
Aging also shifts the immune system toward chronic, low-grade inflammation and an accumulation of worn-out memory T cells that respond poorly to new threats. Regulatory T cells, which normally prevent the immune system from overreacting, become more numerous and more active with age, potentially suppressing the very responses needed to fight a new infection. Children and young adults, by contrast, have a thymus that’s still actively churning out diverse, responsive T cells, which helps explain why they typically experience milder disease.
Memory B Cells and Antibody Evolution
One of the more encouraging aspects of the immune response to COVID is how memory B cells mature over time. After an initial infection, these cells continue to evolve for at least a year, producing increasingly potent and broadly effective antibodies. Through a process of gradual genetic refinement, the antibodies generated by memory B cells become better at recognizing not just the original virus but also mutated variants.
Circulating antibodies, on the other hand, don’t stick around as long. Neutralizing antibody levels decline with a half-life that can be as short as 47 days for the original strain and even shorter against some variants. This is why antibody levels measured by a blood test may drop within months, even though immune memory remains intact at a deeper level. The distinction matters: your body may not have antibodies circulating and ready to go, but memory B cells can ramp up production quickly upon re-exposure.
How Variants Outmaneuver Existing Immunity
SARS-CoV-2 has proven remarkably adept at evolving to dodge the antibodies your immune system already made. The Omicron variant, for example, carries roughly 60 mutations across its genome, with the heaviest concentration in the spike protein that antibodies target. Key mutations in the receptor-binding domain, the part of the spike that locks onto human cells, allow the virus to escape recognition by antibodies generated from earlier infections or vaccinations.
Specific mutations at positions E484, Q493, and K417 on the spike protein are particularly effective at evading different classes of antibodies. Some mutations, like K417N and N501Y, do double duty: they help the virus escape immune detection while simultaneously improving its ability to bind to human cells, making it both more evasive and more infectious. Newer subvariants like EG.5 carry additional spike mutations that further erode the effectiveness of existing antibody responses. This ongoing evolution is the primary reason why immunity from a single infection or vaccination wanes against newer strains.
Autoimmunity and Long-Term Immune Disruption
Perhaps the most concerning long-term effect of COVID on the immune system is the emergence of autoantibodies, immune proteins that mistakenly target the body’s own tissues. Research published in Nature Communications found that new autoantibodies against a wide range of the body’s own proteins appeared after SARS-CoV-2 infection and remained elevated for at least 12 months. These weren’t limited to severe cases; they emerged across mild to severe infections.
Some of these autoantibodies appear to work through molecular mimicry, where a portion of the virus’s spike protein resembles human proteins closely enough that the immune system gets confused and attacks both. A subset of autoantibodies detected in COVID patients has been shown to interfere with immune signaling, increase viral loads, and reduce T-cell and B-cell populations. The presence of these autoantibodies is associated with neuropsychiatric symptoms after COVID, suggesting they may play a role in brain fog, fatigue, and other neurological features of long COVID.
Hybrid Immunity Builds a Stronger Response
People who have both recovered from COVID and received vaccination develop what’s known as hybrid immunity, and it appears to produce a qualitatively different immune response than either infection or vaccination alone. When exposed to spike protein, vaccinated COVID survivors show stronger activation of CD4+ T cells, with higher expression of markers indicating both robust antiviral activity and better immune regulation. Their CD8+ T cells also produce more of the molecules used to kill infected cells.
The key advantage of hybrid immunity isn’t just stronger responses but more balanced ones. Vaccinated individuals who previously had COVID show enhanced production of both inflammatory and regulatory signals, meaning their immune system can fight the virus aggressively while also keeping inflammation in check. This dual capability likely contributes to the lower rates of severe disease seen in people with hybrid immunity compared to those relying on natural infection alone. Combined with the ongoing maturation of memory B cells, which produce increasingly broad antibodies over time, hybrid immunity represents the most durable protection currently available against both the original virus and its evolving variants.